The invention relates to modified single domain antigen binding molecules, e.g., SDAB molecules, in particular TNFa-binding SDAB molecules. Method of preparing, and using the modified single domain antigen binding molecules described herein, to treat, e.g., TN Fa-associated disorders, are also disclosed.